Filters
Content type: News, Editors' picks, About HIV
Topic: Injectable & long-acting PrEP
The antiretroviral drug cabotegavir, administered every eight weeks as an injection, has been shown to be safe and effective in preventing HIV infection in men who have sex with men. Studies in women are ongoing and scientists are also working on a long-acting PrEP implant.
HIV Medicine Association
Medscape (requires free registration)
ViiV press release
MSF
UNAIDS 
World Health Organization
Nature (editorial)
Medicines Patent Pool